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In addition to its major role in the regulation of somatic growth, growth hormone (GH)
signaling has profound effects on function of various tissues in the body. However, the cel-
lular location where the GH signaling exerts its effect on metabolic homeostasis remains
largely unknown. Here, we briefly review recent progress and insights from mice with GH
receptor deletion specifically in adipocytes, macrophages, hepatocytes, pancreatic β-cells,
and skeletal muscle cell types. These studies have greatly enhanced our understanding of
the GH–IGF-I physiological function.
Keywords: GH signaling, mice, GHRKO, hepatic GHR signaling, adipocytes, macrophages
INTRODUCTION
In addition to its major role in the regulation of somatic growth
(1), growth hormone (GH) is a major regulator of gene expres-
sion and protein synthesis in the liver, fat mobilization in the
metabolically active tissues, and organ response to insulin (1).
Hepatocytes, pancreatic beta cells, adipocytes, macrophages, and
muscle cells are among the cell types that express GH receptors
and are critical targets for GH action. Effects of GH on these
cells are thought to be predominantly direct, whereas many of its
effects are mediated through circulating insulin-like growth fac-
tor I (IGF-I) or local (auto/paracrine) IGF-I actions. In 1997, the
Kopchick laboratory reported creating mice with targeted deletion
(“knockout”) of the GH receptor and they resulting profound
GH resistance, reduction of circulating IGF-I levels, disruption
of the negative IGF-I feedback, and increase in plasma levels of
GH (2). Studies of these animals provided much new information
about physiological actions in mammals (3). Mice homozygous
for GHR deletion (GHR-KO mice) have markedly increased adi-
posity and yet are metabolically “healthy” with reduced levels of
insulin, reduced or normal levels of glucose, enhanced insulin sen-
sitivity, increased adiponectin levels, reduced blood pressure, and
significantly extended longevity of both females and males (3). The
fascinating consequences of the global deletion of GH receptors in
GHR-KO mice stimulated interest in identifying the role of GH sig-
naling in different target organs of this hormone. It is believed that
GH exerts systemic effects primarily through liver-derived IGF-I
and adipocyte-derived circulating proteins, such as adipokines and
cytokines. Surprisingly, liver-specific IGF-I deletion in mice (LID)
(4) has almost no effect on postnatal somatic growth. Moreover,
LID mice were found to have hyperinsulinemia and muscle insulin
resistance (5). Insulin resistance of these animals was ascribed to
stimulation of GH release in response to reduced levels of IGF-I in
the circulation. In support of this interpretation suppressing GH
level by GH-releasing hormone antagonist dramatically increased
insulin sensitivity in these mice (5). These data suggest that GH
plays a direct role in systemic carbohydrate metabolism, glucose
homeostasis, and insulin action. However, the cellular location of
the GH actions remains largely unknown. In this article, we will
briefly review the results of studies aimed at identifying the role of
different organs or cell types in mediating the physiological effects
of GH.
TISSUE-SPECIFIC GHR SIGNALING
Utilizing the Cre/LoxP system, recent studies of mice with GH
receptor deletion specifically in various cell types have greatly
enhanced our understanding of the GH–IGF-I axis. Results
obtained in these animals provide novel insights into the critical
role of the local GH signaling in the particular tissues. Published
evidence indicated that each of these organ-specific GHRKO mice
has its own unique set of physiological and metabolic features.
Some of the findings are consistent with the results obtained in the
whole-body GHR null mice, while others are seen only in specific
organ GHRKO mutants, suggesting that the existence of previ-
ously unknown interactions between GH target tissues. The most
important phenotypical changes in mice with organ-specific dis-
ruption of GHR signaling are summarized in Table 1 and Figure 1
and are discussed below.
GHR SIGNALING DISRUPTION IN ADIPOCYTES AND
MACROPHAGES
Growth hormone exerts profound effects on adipose tissue. Over-
all, GH regulates adipocyte proliferation and differentiation and
decreases fat deposition by both inhibiting triglyceride accumula-
tion and increasing lipolysis. Furthermore, GH has been shown
to negatively regulate the secretion of adipokines such as lep-
tin and adiponectin. Compared to littermate control mice, the
whole-body GHR null mice have higher percent body fat with
elevated circulating adiponectin and leptin levels. Intriguingly,
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Table 1 | Major phenotypical and metabolic changes in mice with organ-specific disruption of GHR signaling.
Name Tissue Cre Life
Span
Strain Obesity Blood
GH
Blood
IGF-I
Insulin
sensitivity
Glucose
tolerance
Other metabolic changes
GHRKO Whole-body ↑ Ola-BALB/c ↑ ↑ ↓ ↑ ↑ ↑ Adiponectin, leptin
Fat-GHRKO Adipocytes aP2 ? C57BL/G ↑ N.C. N.C. N.C. N.C.
Mac-
GHRKO
Macrophages LysM ? C57BL/6 ↑ HFD N.C. ↓ HFD ↓ HFD Metabolic normal fed with
normal chow
Liv-GHRKO Hepatocytes Albumin ? 129/SvJ-
C57BL/6
N.C. ↑ ↓ ↓ ↓ Impaired lipid homeostasis
and hepatic steatosis (6)
Liv-GHRKO Hepatocytes Albumin ? C57BL/6 N.C. ↑ ↓ N.C. N.C. Fatty liver phenotype only in
male (7)
β-GHRKO Pancreatic
β-cells
Rip ? C57BL/6 N.C. N.C. ↓ HFD ↓ HFD Lost the first–phase GSIS and
glucose intolerance on HFD
Mus-
GHRKO
Muscle cells Mef-2c ? 129/SvJ-
C57BL/6
↑ ? ? ↓ ↓ Marked metabolic
abnormalities (8)
Mus-
GHRKO
Muscle cells Mck ? C57BL/
6×C3H
↓ N.C. N.C. ↑ ↑ Decreased systemic
inflammation, muscle and
hepatic triglyceride content (9)
?, Information not available.
FIGURE 1 |Tissue-specific GHR knockouts using promoter Cre-loxP
recombination..
these mutant mice are found to have preferential accumulation
of subcutaneous fat depots, while visceral fat pads in animals with
different genetic background are either less affected or diminished
in size as compared to the control mice.
List et al. have recently disrupted GHR in white adipose tis-
sue (WAT) under the aP2-cre promoter/enhancer and produced
Fat-GHRKO mice (10). Fat-GHRKO mice share some characteris-
tics with whole-body GHRKO mice; they are obese with increased
total body fat, enlarged adipocyte size, and increased circulating
leptin levels (10). However, unlike global GHR null mice, these
mice show no signs of metabolic improvements and have normal
glucose homeostasis and normal/decreased levels of adiponectin
(10). In interpreting these unexpected findings, it is necessary to
consider that GHR was likely deleted not only in adipocyte but also
in other cell types, including macrophages (11). Further studies
using different Cre lines of mice, such as adiponectin-Cre trans-
genic mice, would be necessary to elucidate the direct role of GH
in adipocytes from different depots. We would also add that much
was learned about the role of insulin signaling in adipose tissue
from studies in FIRKO mice, which were generated using the same
aP2-cre Tg mice (12).
Infiltration into adipose tissue by macrophage (MΦ) has
emerged as an important component in the pathogenesis of diet-
induced obesity (DIO) and insulin resistance (13). The invading
macrophages have been shown to be a major source of proinflam-
matory cytokines, such as IL-1β and TNF-α (14), and thus, are
contributors to the establishment of the low-grade chronic inflam-
matory state associated with obesity. In order to understand the
role of GH signaling in macrophage invasion, MΦ-specific GH
receptor-KO (MacGHR-KO) mice were created in R. K. Menon’s
group by crossing LysMcre mice with GHR exon 4 floxed mice
(15). Fed with a normal chow diet, MacGHR-KO exhibited normal
growth profiles and metabolic characteristics (15). Compared to
normal animals fed HFD, MacGHR-KO mice on the same diet had
greater impairments of glucose tolerance and insulin sensitivity
as revealed by insulin and glucose tolerance tests (15). More-
over, increased visceral WAT, enlarged adipocyte size, increased
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MΦ invasion, elevated proinflammatory cytokines, and attenuated
insulin-stimulated Akt phosphorylation were detected in the WAT
of HFD fed MacGHR-KO mice. These results suggest that MΦ-
specific GH signaling plays an important role in the pathogenesis
of DIO.
HEPATIC GHR SIGNALING
Hepatic GHRs have been shown to be expressed at high levels and
therefore the liver is highly responsive to GH signaling. The liver
is also the major site of IGF-I secretion and the main source of
circulating IGF-I. Due to absence of negative feedback of serum
IGF-I, LID mice have high circulating level of GH. The elevated
GH secretion counteracts insulin action, decreasing insulin sensi-
tivity, and glucose tolerance (5). These results are consistent with
the ability of GH to affect various tissues via direct action, which
might be independent of IGF-I. However, the precise contribution
of GH action liver remains to be elucidated.
Using a similar approach, two independent groups have gen-
erated two lines of mice with liver-specific disruption of GHR
(LivGHR-KO) under the albumin-cre driver (6, 7). Fan et al.
reported that LivGHR-KO mice have normal body size and bone
linear growth despite profound suppression of circulating IGF-
I level (6). Subsequently, List et al. found that Liv-GHRKO
mice generated in Kopchick’s group were smaller than littermate
controls, with their body length and body weight significantly
decreased in both sexes (7). In the first report (6), LivGHR-
KO mice showed the characteristics of metabolic abnormalities
including hyperinsulinemia, impaired insulin signaling, abnormal
glucose intolerance, hepatic steatosis, and altered lipid home-
ostasis. In contrast, in the second line of LivGHR-KO mice (7),
all these metabolic parameters remained unaltered as compared
to the controls except that fatty livers were manifested in male
LivGHR-KO mice. The difference in genetic backgrounds and the
diet employed in these two studies may account for the different
phenotypes.
GHR SIGNALING IN SKELETAL MUSCLE
Growth hormone–IGF axis has a dramatic impact on skeletal mus-
cle growth and anabolism. GH has been shown to stimulate cell
mitosis, increase protein translation, promote satellite cell prolif-
eration, and inhibit apoptosis (16, 17). There is also evidence that
GH can affect muscle fiber composition (18). However, it will be
important to distinguish between direct actions of GH and sec-
ondary IGF-I mediated GH effects. Using whole-body GHRKO
mice, Sotiropoulos et al. found that GH enlarged skeletal muscle
size by increasing myofiber size in the IGF-I independent man-
ner (19). Interestingly, they have shown that GH had no impact
on cell number, proliferation, or differentiation of the progeni-
tor cells (19). These data indicate the importance of GH in skeletal
muscle physiology via IGF-I independent mechanisms responsible
for these effects.
The Clemens laboratory has recently characterized the novel
line of skeletal muscle-specific GHR (MusGHR-KO) and IGF-
IR (MusIGFR-KO-1) knockout mice under myocyte-specific
enhancer factor 2C (mef-2c-73k) promoter (8). In contrast
with MusIGFR-KO mutant mice, MusGHR-KO-1 mice exhib-
ited marked metabolic abnormalities including peripheral obesity,
insulin resistance, and impaired glucose tolerance. Intriguingly, a
second line of skeletal muscle-specific GHR knockout (MusGHR-
KO-2) mice developed by LeRoith’s group [using muscle creatine
kinase (MCK) promoter] were found to have the opposite meta-
bolic phenotype (9). The MusGHR-KO-2 mice had reduced fat
mass, improved metabolic markers when fed with normal diet,
and were protected against metabolic impairments in the high-fat-
diet settings. Taken together, these studies have indicated that that
GHR signaling in different subsets of muscle cells could have dif-
ferent metabolic effects. There remain important areas for further
investigation. Furthermore, in interpreting these findings using
mef-2c and MCK cre transgenic mice, it is necessary to consider
that GHR was likely deleted not only in skeletal muscle cells but
also in cardiac muscles.
GHR SIGNALING DISRUPTION IN BETA CELLS
The ability of pancreatic β-cells to synthesize and secrete insulin
is the key to overcome the hyperglycemia and maintain the glu-
cose homeostasis in the settings of insulin resistance. Impairment
to secreting sufficient insulin levels in the face of hyperglycemia
leads to the pathogenesis of diabetes (20). GH has been shown to
play an important role in maintaining pancreatic β-cells mass (21),
regulating β-cell proliferation (22), and differentiation (23) and
stimulating gene expression of components in the insulin signaling
pathway in these cells.
In order to elucidate the specific role of GH signaling pan-
creatic β-cells. Wu et al. generated β cell-specific GHR null mice
(βGHRKO) employing RIP-Cre recombinase (24). βGHRKO mice
developed impaired glucose-stimulated insulin secretion (GSIS)
while no alteration was revealed in GTT, ITT test, or β cell stain-
ing. Intriguingly, when fed with HFD, βGHRKO mice lost the
first-phase GSIS and developed exacerbated glucose intolerance.
These mutant mice exhibited a dramatic defect inβ cell hyperplasia
due to decreased cell proliferation in response to HFD challenge.
These data point out that GH signaling in β cells is pivotal in the
process of compensatory cell proliferation and insulin secretion in
the state of the DIO.
PERSPECTIVES
There has been considerable recent progress in unraveling the
effects and mechanisms of tissue-specific actions of GH signal-
ing. However, many gaps remain in our understanding of these
processes. For example, one future imperative will be to explore
the GH action and signaling in tissues for which GH action has
not been clearly evaluated. In particular, further study of key cell
populations at the specific brain regions or in certain brain cell
populations will be critical, with special attention to (1) hypothal-
amus,which is considered a key regulator of food intake and energy
expenditure in mammals; (2) hippocampus, which is critical for
learning and memory and is sensitive to hormonal fluctuations;
and (3) glial cells including astrocytes, which have emerged as
active players in CNS metabolic activities. It will be important
to use these novel tissue/cell-specific GHR null mice to further
dissect the functioning of the somatotropic axis, elucidate the
mechanisms of cross-talk among different tissues, and determine
the interactions between genes and environment in the context of
development and aging. Such studies will offer critical insight into
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the basic physiological processes and molecular mechanisms that
regulate metabolism and insulin action.
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